News & Updates
Filter by Specialty:
Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
Prexasertib works in select patients with recurrent ovarian cancer
14 Oct 2022Sotagliflozin may offer cardiorenal protection for adults with T1D
13 Oct 2022
byAudrey Abella
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Sotagliflozin may offer cardiorenal protection for adults with T1D
13 Oct 2022Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension
13 Oct 2022
The combination of digital therapeutics (DTx) with the treatment-as-usual (TAU) strategy for essential hypertension is more cost-effective than TAU alone, a recent Japan study has found.